Target therapy in treatment of HER2-positive breast cancer

The breast cancer (BC) wins first place in structure of oncological incidence of the female population around the world. The special place is occupied by tumors with a superfluous expression of HER2 of a factor which is defined at 25–30 % of patients. Interest to suchpatients is defined by an aggres...

Full description

Bibliographic Details
Published in:	Сибирский онкологический журнал
Main Authors:	A. S. Belokhvostova, I. A. Smirnova, A. A. Enileeva
Format:	Article
Language:	Russian
Published:	Russian Academy of Sciences, Tomsk National Research Medical Center 2016-02-01
Subjects:	breast cancer her2 trastuzumab (herceptin®)
Online Access:	https://www.siboncoj.ru/jour/article/view/103

Similar Items

Investigating the Combination therapy effect of Trastuzumab and Idarubicin on growth inhibition of HER2-positive breast cancer cells line (SK-BR-3)
by: Moslem Afrakhteh, et al.
Published: (2017-11-01)

Systemic investigation of inetetamab in combination with small molecules to treat HER2-overexpressing breast and gastric cancers
by: Deng Lan, et al.
Published: (2023-01-01)

Herceptin® (trastuzumab) in HER2-positive early breast cancer: protocol for a systematic review and cumulative network meta-analysis
by: Florence R. Wilson, et al.
Published: (2017-10-01)

Long-term follow-up of early stage HER2-positive breast cancer patients treated with trastuzumab: A population-based real world multicenter cohort study
by: Sander Ellegård, et al.
Published: (2022-08-01)

Trastuzumab: updated mechanisms of action and resistance in breast cancer
by: Francois X. Claret, et al.
Published: (2012-06-01)

Shorter Durations of Anti-HER2 Therapy for Patients with Early-Stage, HER2-Positive Breast Cancer: The Physician Perspective
by: Michelle Bradbury, et al.
Published: (2023-12-01)

Damaging non-synonymous mutations in the extracellular domain of HER2 potentially alter the efficacy of Herceptin-mediated breast cancer therapy
by: Arijit Samanta, et al.
Published: (2025-09-01)

Durable and Complete Response to Herceptin Monotherapy in Patients with Metastatic Gastroesophageal Cancer
by: Brenen P. Swofford, et al.
Published: (2017-12-01)

Developments in the Management of Metastatic HER2-Positive Breast Cancer: A Review
by: Julie Lebert, et al.
Published: (2022-04-01)

Anti-HER2 induced myeloid cell alterations correspond with increasing vascular maturation in a murine model of HER2+ breast cancer
by: Meghan J. Bloom, et al.
Published: (2020-04-01)

Hypofunction of macrophage chemotaxis contributes to defective efficacy of herceptin in HER2-positive breast cancer patients
by: Yu Song, et al.
Published: (2024-12-01)

Improving treatment outcomes for patients with HER2‑positive breast cancer using neoadjuvant double HER2 blockade
by: V. F. Semiglazov, et al.
Published: (2024-11-01)

Uptake of Trastuzumab Biosimilars for the Treatment of HER2-Positive Breast Cancer: A Real-World Experience from a Cancer Center
by: Michela Piezzo, et al.
Published: (2021-05-01)

Multilineal treatment strategy of HER2-positive metastatic breast cancer (clinical case)
by: A. F. Nasretdinov, et al.
Published: (2021-06-01)

Macrotroponin interference and association with cardiotoxicity in patients receiving cardiotoxic breast cancer therapy: a pilot study
by: Andrea Soosaipillai, et al.
Published: (2025-02-01)

A bibliometric analysis of HER2-positive breast cancer: 1987–2024
by: Sherlissa Ali-Thompson, et al.
Published: (2024-05-01)

HER2-Positive Breast Cancer—Current Treatment Management and New Therapeutic Methods for Brain Metastasis
by: Hanna Miski, et al.
Published: (2025-05-01)

Comparison of T-DM1 and trastuzumab-pertuzumab in HER2-positive breast cancer patients with residual disease after neoadjuvant therapy: a retrospective study
by: Junxiao Wang, et al.
Published: (2025-07-01)

Dual anti-HER2 blockade in late-line treatment of metastatic HER2-positive breast cancer
by: M. A. Frolova, et al.
Published: (2021-12-01)

Neoadjuvant chemotherapy with or without anthracyclines in combination with single HER2-targeted therapy in HER2-positive breast cancer
by: Anshul Gupta, et al.
Published: (2023-01-01)

Strategy and Status of Neoadjuvant Therapy for HER2-positive Breast Cancer
by: LIU Yunjiang, et al.
Published: (2024-01-01)

Trastuzumab resistance in HER2-positive breast cancer: Mechanisms, emerging biomarkers and targeting agents
by: Zhen-hao Wang, et al.
Published: (2022-10-01)

Trastuzumab deruxtecan: A quantum leap in HER2-positive breast cancer
by: Manikandan Dhanushkodi
Published: (2019-01-01)

A case of HER-2-positive recurrent breast cancer showing a clinically complete response to trastuzumab-containing chemotherapy after primary treatment of triple-negative breast cancer
by: Haruta Rumi, et al.
Published: (2011-11-01)

How I treat HER2-low advanced breast cancer
by: Ilana Schlam, et al.
Published: (2023-02-01)

Is switching to T-DM1 still justified in HER2-negative residual breast cancer after neoadjuvant systemic therapy?
by: Wiebren Tjalma, et al.
Published: (2025-06-01)

Change in HER-2/neu Status from Negative to Positive following Treatment in Breast Cancer: A Case Report
by: Lakshmi Sivarajan, et al.
Published: (2011-01-01)

HER-2-positive metastatic breast cancer: new possibilities for therapy
by: E. V. Artamonova, et al.
Published: (2014-07-01)

Prevalence of Cardiotoxicity Secondary to Trastuzumab in Patients with HER-2-Positive Breast Cancer in Southeast Mexico
by: Luz I. Pascual-Mathey, et al.
Published: (2024-09-01)

Current approaches to the treatment of HER2‑positive breast cancer with brain metastases
by: T. Yu. Semiglazova, et al.
Published: (2021-06-01)

Mechanisms of reduced efficacy of HER2-targeted therapy in HER2-low breast cancer by long-term nicotine exposure in patient-derived xenograft mouse tumor models
by: Yu-Hsuan Lin, et al.
Published: (2025-04-01)

HER2-Low Breast Cancer: Current Landscape and Future Prospects
by: Shirman Y, et al.
Published: (2023-08-01)

Involvement of microRNAs-449/FASN axis in response to trastuzumab therapy in HER2-positive breast cancer
by: Ana Lameirinhas, et al.
Published: (2025-03-01)

Trastuzumab emtansine of the treatment of HER2-positive breast cancer with brain metatases
by: L. Yu. Vladimirova, et al.
Published: (2020-12-01)

Trastuzumab and ECG Changes Dilemma
by: Azin Alizadehasl, et al.
Published: (2023-04-01)

Efficacy and Safety Profile of Different Schedules of Adjuvant Trastuzumab Therapy among Patients with HER2-Positive Breast Cancer: Real-World Experience from a Tertiary Cancer Center in South India
by: Nandini Devi Rajan, et al.
Published: (2025-01-01)

Effect of HER2 Ile655Val polymorphism on the response to trastuzumab treatment in HER2-positive breast cancer patients
by: Zohreh Gheibipour, et al.
Published: (2025-07-01)

Pyrotinib and trastuzumab combination treatment synergistically overcomes HER2 dependency in HER2-positive breast cancer: insights from the PHILA trialResearch in context
by: Shuning Liu, et al.
Published: (2024-11-01)

Potential prognostic value of HER2/CEP17 FISH ratio in HER2-positive non-metastatic breast cancer: a real-world study
by: Fangchao Zheng, et al.
Published: (2025-05-01)

Novel approaches to target HER2-positive breast cancer: trastuzumab emtansine
by: Recondo G Jr, et al.
Published: (2016-05-01)